Loretta Szczotka-Flynn, OD
Optometrist · Cleveland, OHNPI 1083647390
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.0%. 2025 is the largest year on record at $5,236, 2.5 times the $2,137 reported in 2019. Among optometrist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $154.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Coopervision Inc.$3K
- Johnson & Johnson Vision Care, Inc.$2K
- Alcon$1K
- Visioneering Technologies, Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- plus $3K from 13 others
Across 120 payments — averaging $3118.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$255K
- Johnson & Johnson Vision Care, Inc.$119K
What the payments were for
- Consulting fees$3,82528%
- Speaking & faculty fees$2,70019%
- Travel & lodging$1,2679%
- Food & beverage$6,08244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $3,192 |
| Coopervision Inc. | 18 | $2,516 |
| Johnson & Johnson Vision Care, Inc. | 5 | $1,860 |
| Alcon | 12 | $1,352 |
| Visioneering Technologies, Inc. | 3 | $1,169 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $1,164 |
| Biotissue Holdings Inc. | 4 | $492 |
| Oyster Point Pharma, Inc. | 8 | $471 |
| Bausch & Lomb Americas Inc. | 4 | $334 |
| AbbVie(2 entities) | 7 | $324 |
| Novartis | 7 | $285 |
| Glaukos Corporation | 2 | $223 |
| Dompe US, Inc. | 2 | $155 |
| Shire North American Group Inc | 2 | $132 |
| Quidel Corporation | 1 | $90 |
| Tarsus Pharmaceuticals, Inc. | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEN LENS$2,900
- Acuvue$1,500
- Onefit Contact Lens$1,462
- TYRVAYA$316
- Prokera$297
- Paragon CRT$275
- INFUSE$228
- XIIDRA$220
- Rose K Contact Lens$150
- Clareon PanOptix Pro$145
- ALDEN SCLERAL ZENLENS$144
- Precision7$132
- Precision 7$132
- AmnioGraft$127
- Oxervate$125
- AIR OPTIX$123
- Photrexa$113
- BIOTRUE$103
How this compares
$13,874 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 13 | $16,943 |
| RestasisCyclosporine | 27 | $15,970 |
| CequaCyclosporine | 11 | $9,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $334 | $16,94313 claims |
| AbbVieRestasis | $324 | $15,97027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Cleveland
- Thomas ChesterCleveland$300K
- Sara HitchmanCleveland$20K
- Thomas StokkermansCleveland$12K
- Joseph KeaneyCleveland$11K
- Mile BrujicBowling Green$1.3M
- Gregory DenaeyerColumbus$846K
- Cory LappinMontgomery$367K
- Chris SmileyColumbus$305K
- Carly RoseCincinnati$203K
- Wendy HallierReynoldsburg$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.